Do probiotics benefit patients who are prescribed antibiotics?

Probiotics for Patients on Antibiotics

For adults and children receiving antibiotics, specific probiotic strains should be used to prevent Clostridioides difficile infection, particularly in high-risk populations, though the benefit for general antibiotic-associated diarrhea is modest and strain-dependent. 1

Recommended Probiotic Strains

The American Gastroenterological Association (AGA) provides conditional recommendations for specific strains when preventing C. difficile infection in patients on antibiotics: 1, 2

• Saccharomyces boulardii (RR 0.41; 95% CI 0.22-0.79) 1
• Two-strain combination: L. acidophilus CL1285 + L. casei LBC80R (RR 0.22; 95% CI 0.11-0.42) 1
• Three-strain combination: L. acidophilus + L. delbrueckii subsp. bulgaricus + B. bifidum (RR 0.35; 95% CI 0.15-0.85) 1
• Four-strain combination: L. acidophilus + L. delbrueckii subsp. bulgaricus + B. bifidum + S. salivarius subsp. thermophilus (RR 0.28; 95% CI 0.11-0.67) 1

Clinical Efficacy by Outcome

C. difficile Infection Prevention

The most recent Cochrane review (2025) analyzing 38 trials with 13,179 participants demonstrates that probiotics reduce C. difficile infection risk by 50% (RR 0.50; 95% CI 0.38-0.64), with an absolute risk reduction of 1.6% (number needed to treat = 65). 3 However, this benefit is primarily driven by high-risk populations (>15% baseline risk), with minimal effect in low-risk outpatient settings. 1

Antibiotic-Associated Diarrhea

Probiotics reduce antibiotic-associated diarrhea by 33% (RR 0.67; 95% CI 0.57-0.78), with an absolute risk reduction of 9%. 3 Outpatient-specific data shows similar benefits (RR 0.49; 95% CI 0.36-0.66). 4

Microbiome Restoration

Critical caveat: Despite marketing claims, evidence does not support that probiotics restore the microbiome to its pre-antibiotic state. 5, 6 A 2024 systematic review found heterogeneous results—some studies showed probiotics counteracting diversity changes, others showed exacerbation or delayed recovery, and many showed no effect. 6

Risk Stratification for Use

High-Risk Patients (Recommend Probiotics)

Patients with >15% baseline risk of C. difficile infection benefit most: 1

• Hospitalized patients on broad-spectrum antibiotics
• Elderly patients (>65 years)
• Patients with recent healthcare exposure
• Those on multiple antibiotics or prolonged courses

Low-Risk Patients (Probiotics Optional)

Outpatients with <2% baseline risk may reasonably decline probiotics given: 1, 2

• Minimal absolute benefit
• Associated costs
• Potential harms in immunocompromised patients

Safety Profile

Probiotics likely result in a small absolute risk reduction of adverse events (1.7% reduction; RR 0.86; 95% CI 0.72-1.01). 3 Common adverse events in both groups include abdominal cramping, nausea, and flatulence. 3

Contraindications: Severely immunocompromised patients should avoid probiotics due to potential harm. 1, 2

Timing and Dosing

Probiotics should be initiated upon antibiotic start or within 48 hours to maximize efficacy in preventing antibiotic-associated dysbiosis. 7 The evidence supports adequate dosing of specific strains rather than generic "probiotic" products. 7

Evidence Quality and Limitations

The overall certainty of evidence is low to moderate due to: 1, 3

• High heterogeneity across studies (different populations, antibiotics, settings)
• Risk of bias in most trials (unclear allocation concealment, selective reporting)
• Potential publication bias (many registered trials never published)
• Industry funding in 28 of 47 studies 1
• Missing outcome data in 27 of 38 trials (2-45% missing) 3

Despite these limitations, the 2025 Cochrane review confirms results remain robust to sensitivity analyses. 3

Practical Implementation

For high-risk inpatients: Use one of the four AGA-recommended strain combinations starting with antibiotic initiation. 1, 2

For low-risk outpatients: Discuss cost-benefit ratio; probiotics provide modest absolute benefit (NNT=65 for C. difficile prevention). 3 Patients prioritizing cost avoidance may reasonably decline. 1, 2

Avoid: Generic multi-strain products without evidence for the specific strains listed above. 7